Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.77 USD
+0.04 (1.07%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.77 USD
+0.04 (1.07%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.
Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
by Zacks Equity Research
Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.
NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session
by Zacks Equity Research
NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
by Zacks Equity Research
Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.
Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
by Zacks Equity Research
Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.
Celgene (CELG) Otezla Approved in Japan for Two Indications
by Zacks Equity Research
Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.
Roche Presents Positive Follicular Lymphoma Data on Gazvya
by Zacks Equity Research
Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
by Zacks Equity Research
Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint
New Strong Buy Stocks for December 5th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
by Zacks Equity Research
Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101
Foamix Completes Enrolment in Phase III Acne Drug Studies
by Zacks Equity Research
Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it is expanding its sales force to reach primary care physicians.
New Strong Buy Stocks for November 21st
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday